No Data
No Data
Retail Investors Who Hold 42% of Zhejiang Jingxin Pharmaceutical Co., Ltd. (SZSE:002020) Gained 5.7%, Insiders Profited as Well
Key Insights Significant control over Zhejiang Jingxin Pharmaceutical by retail investors implies that the general public has more power to influence management and governance-related decisions 50%
Zhejiang Jingxin Pharmaceutical (002020.SZ): The admission and sales of Jinkening are proceeding in an orderly manner.
Zhejiang Jingxin Pharmaceutical (002020.SZ) stated on the investor communication platform on July 3 that the hospitalization and sales of Jinnuoning are proceeding in an orderly manner. The company's current operational status is normal. Please pay attention to the periodic reports for specific company business data.
Zhejiang Jingxin Pharmaceutical (002020.SZ): preparing materials for the upcoming medical insurance negotiations for Jinnuoning.
Jingxin Pharmaceutical (002020.SZ) stated on the investor interaction platform on July 3rd that the company is preparing materials for the upcoming medical insurance negotiation for Jinnuoning. Currently, the company's other products are not involved in medical insurance.
Zhejiang Jingxin Pharmaceutical Gets European Certificate for Animal Antibiotic
Zhejiang Jingxin Pharmaceutical Co (SHE:002020) received the European Pharmacopoeia Certificate of Suitability for active pharmaceutical ingredients from the European Directorate for the Quality of Me
Here's Why Zhejiang Jingxin Pharmaceutical (SZSE:002020) Can Manage Its Debt Responsibly
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says 'The biggest investment risk is not the volatility of prices, but whether you will
Jingxin Pharmaceutical (002020.SZ): The artificial large blood vessel project has now entered the small-scale human trial stage
Gelonghui, May 30丨Jingxin Pharmaceutical (002020.SZ) said on the investor interactive platform that the company's artificial large blood vessel project has now entered the small-scale human trial stage. The time to market also depends on the progress of testing and other related work.
No Data